196 related articles for article (PubMed ID: 29912453)
1. Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial.
de Vries RD; Altenburg AF; Nieuwkoop NJ; de Bruin E; van Trierum SE; Pronk MR; Lamers MM; Richard M; Nieuwenhuijse DF; Koopmans MPG; Kreijtz JHCM; Fouchier RAM; Osterhaus ADME; Sutter G; Rimmelzwaan GF
J Infect Dis; 2018 Jul; 218(4):614-623. PubMed ID: 29912453
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
3. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
[TBL] [Abstract][Full Text] [Related]
4. Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene.
Kamlangdee A; Kingstad-Bakke B; Anderson TK; Goldberg TL; Osorio JE
J Virol; 2014 Nov; 88(22):13300-9. PubMed ID: 25210173
[TBL] [Abstract][Full Text] [Related]
5. Recombinant parainfluenza virus 5 expressing clade 2.3.4.4b H5 hemagglutinin protein confers broad protection against H5Ny influenza viruses.
Li H; Sun H; Tao M; Han Q; Yu H; Li J; Lu X; Tong Q; Pu J; Sun Y; Liu L; Liu J; Sun H
J Virol; 2024 Mar; 98(3):e0112923. PubMed ID: 38305155
[TBL] [Abstract][Full Text] [Related]
6. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
[TBL] [Abstract][Full Text] [Related]
7. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
Kamlangdee A; Kingstad-Bakke B; Osorio JE
J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
[TBL] [Abstract][Full Text] [Related]
8. Broadly Reactive IgG Responses to Heterologous H5 Prime-Boost Influenza Vaccination Are Shaped by Antigenic Relatedness to Priming Strains.
Wang J; Li D; Perry S; Hilchey SP; Wiltse A; Treanor JJ; Sangster MY; Zand MS
mBio; 2021 Aug; 12(4):e0044921. PubMed ID: 34225490
[TBL] [Abstract][Full Text] [Related]
9. Protective efficacy of an inactivated chimeric H5 avian influenza vaccine against H5 highly pathogenic avian influenza virus clades 2.3.4.4 and 2.3.2.1.
Li J; Hou G; Wang Y; Wang S; Cheng S; Peng C; Jiang W
J Gen Virol; 2018 Dec; 99(12):1600-1607. PubMed ID: 30358528
[TBL] [Abstract][Full Text] [Related]
10. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
[TBL] [Abstract][Full Text] [Related]
11. Homologous and heterologous antigenic matched vaccines containing different H5 hemagglutinins provide variable protection of chickens from the 2014 U.S. H5N8 and H5N2 clade 2.3.4.4 highly pathogenic avian influenza viruses.
Kapczynski DR; Pantin-Jackwood MJ; Spackman E; Chrzastek K; Suarez DL; Swayne DE
Vaccine; 2017 Nov; 35(46):6345-6353. PubMed ID: 28456525
[TBL] [Abstract][Full Text] [Related]
12. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
13. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
14. Cross-Protection by Inactivated H5 Prepandemic Vaccine Seed Strains against Diverse Goose/Guangdong Lineage H5N1 Highly Pathogenic Avian Influenza Viruses.
Criado MF; Sá E Silva M; Lee DH; Salge CAL; Spackman E; Donis R; Wan XF; Swayne DE
J Virol; 2020 Nov; 94(24):. PubMed ID: 32999029
[TBL] [Abstract][Full Text] [Related]
15. H5-based DNA constructs derived from selected highly pathogenic H5N1 avian influenza virus induce high levels of humoral antibodies in Muscovy ducks against low pathogenic viruses.
Guionie O; Niqueux E; Amelot M; Bougeard S; Jestin V
Virol J; 2014 Apr; 11():74. PubMed ID: 24762011
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
17. Vaccine protection of chickens against antigenically diverse H5 highly pathogenic avian influenza isolates with a live HVT vector vaccine expressing the influenza hemagglutinin gene derived from a clade 2.2 avian influenza virus.
Kapczynski DR; Esaki M; Dorsey KM; Jiang H; Jackwood M; Moraes M; Gardin Y
Vaccine; 2015 Feb; 33(9):1197-205. PubMed ID: 25613723
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a Recombinant Turkey Herpesvirus H5 Vaccine Against Challenge With H5N1 Clades 1.1.2 and 2.3.2.1 Highly Pathogenic Avian Influenza Viruses in Domestic Ducks (Anas platyrhynchos domesticus).
Pantin-Jackwood MJ; Kapczynski DR; DeJesus E; Costa-Hurtado M; Dauphin G; Tripodi A; Dunn JR; Swayne DE
Avian Dis; 2016 Mar; 60(1):22-32. PubMed ID: 26953940
[TBL] [Abstract][Full Text] [Related]
19. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.
Ledgerwood JE; Hu Z; Gordon IJ; Yamshchikov G; Enama ME; Plummer S; Bailer R; Pearce MB; Tumpey TM; Koup RA; Mascola JR; Nabel GJ; Graham BS;
Clin Vaccine Immunol; 2012 Nov; 19(11):1792-7. PubMed ID: 22956656
[TBL] [Abstract][Full Text] [Related]
20. Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains.
Rauw F; Palya V; Van Borm S; Welby S; Tatar-Kis T; Gardin Y; Dorsey KM; Aly MM; Hassan MK; Soliman MA; Lambrecht B; van den Berg T
Vaccine; 2011 Mar; 29(14):2590-600. PubMed ID: 21292007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
